MONITORING THE USE OF LINEZOLID IN A THIRD-LEVEL HOSPITAL

Sanabrias Fernández de Sevilla, R; Folguera Olías, C; Calvo Salvador, M; Menchén Viso, B; García Cerezoela, M; Gumiel Baena, I; Sanz Rodríguez, S; Repilado Álvarez, A; Sánchez Guerrero, A.
Pharmacy Department. Hospital Universitario Puerta de Hierro (Majadahonda, Madrid)

OBJECTIVES

- To analyze the evolution of Linezolid (LNZ) consumption from 2009 to 2017 in general in the hospital and in Critical Care Services: Intensive Care Unit (ICU) and Anesthesia-Resuscitation (A-R).
- To see if the introduction of the LNZ generic produced an increase in its use.

MATERIAL AND METHODS

Observational and retrospective study in a third-level hospital.

Farmatools® program was used to obtain LNZ annual consumption since 2009 to 2017:

~ In general in the hospital
~ In the ICU and A-R Services

...of the 3 available LNZ presentations

Tablets  Vials  Oral suspension

The introduction of the LNZ generic in the hospital was in 2016.

A. % variation of global LNZ consumption
B. LNZ DDD/100 stays
C. % variation of consumption in A-R
D. % variation of consumption in ICU

RESULTS

% Variation of global LNZ consumption

% Variation of consumption

A-R

ICU

Table: % Variation of LNZ consumption

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>-</td>
<td>5</td>
<td>18</td>
<td>-5</td>
<td>-4</td>
<td>-6</td>
<td>22</td>
<td>18</td>
<td>3</td>
</tr>
<tr>
<td>B</td>
<td>2.61</td>
<td>2.65</td>
<td>2.91</td>
<td>2.62</td>
<td>2.87</td>
<td>2.74</td>
<td>2.74</td>
<td>4.07</td>
<td>5.12</td>
</tr>
<tr>
<td>C</td>
<td>15.38</td>
<td>10.67</td>
<td>7.92</td>
<td>31.70</td>
<td>-0.74</td>
<td>25.30</td>
<td>12.25</td>
<td>14.50</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>-2.37</td>
<td>0.88</td>
<td>10.80</td>
<td>-1.04</td>
<td>-27.27</td>
<td>13.37</td>
<td>54.13</td>
<td>0.51</td>
<td></td>
</tr>
</tbody>
</table>

CONCLUSIONS

The increase in LNZ consumption appeared 1 year before the availability of the generic.

✓ In the Critical Units, the consumption was affected differently:
  - ICU: increased very significantly and coinciding with the access to the generic.
  - A-R: increased less and one year later than ICU.
✓ The introduction of the LNZ generic contributed, along with other factors, to explain the increase in consumption of it in our hospital.